BackEsperion Therapeutics Overview
Esperion Therapeutics Inc.

Esperion Therapeutics Target Price

Analysts' average 12-month price target for Esperion Therapeutics is $3.2.

Get informed when a big investor buys or sells

+ Follow

Share Price

$3.18

Average Target Price

$3.190.3% upside

4 analysts in the last 4 months

High: $3.28 | Low: $3.16

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-05-01Jefferies$3.283.1% upsideOpen
2026-05-01Piper Sandler$3.160.6% downsideOpen
2026-05-01H.C. Wainwright$3.160.6% downsideOpen
2026-05-01Cantor Fitzgerald$3.160.6% downsideOpen
2025-11-24Piper Sandler$9183% upsideOpen
2025-09-25Cantor FitzgeraldKristen Kluska$9183% upsideOpen
2024-12-17Cantor FitzgeraldKristen Kluska$8151.6% upsideOpen
2022-05-04NeedhamSerge Belanger$12277.4% upsideOpen
2021-05-04Wells FargoDerek Archila$20528.9% upsideOpen

Esperion Therapeutics (ESPR) FAQ

Esperion Therapeutics's target price stands at $3.2. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $3.2 for ESPR implies 0.3% upside versus today's price ($3.18). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Esperion Therapeutics's target price evolved across reporting periods, while the comparison chart places ESPR next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Esperion Therapeutics's reading of $3.2 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.